Philippines Mulls Price-Control Of Additional ‘Essential’ Cancer Drugs
This article was originally published in PharmAsia News
The Philippines is considering additional cancer drugs to be subjected to price controls aimed at lowering the cost of drugs considered “essential.”
You may also be interested in...
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.